LifeSci Capital initiates BlossomHill Therapeutics at Outperform
LifeSci Capital initiated BlossomHill Therapeutics with an Outperform rating and set a $32.00 price target per share, per Benzinga via TradingView News.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.